(Washington, D.C.) — As Congress begins to examine high prescription drug prices, the Pharmaceutical Care Management Association (PCMA) sent letters to several congressional committees highlighting the value pharmacy benefit managers (PBMs) provide to patients and payers as well as outlining
Pennsylvania State Facts & Resources PBM Savings and Patient Impact in Pennsylvania Pharmacy benefit experts secure lower prescription drug costs and enable better health outcomes for patients. PBMs will save Pennsylvanians $45B across all Pennsylvania insurance markets over ten years
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on litigation, filed in the U.S. District Court of the District of Columbia, regarding the Trump administration’s final rule Transparency in Coverage: To avoid higher prescription drug costs for
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued 21 policy solutions supported by America’s pharmacy benefit managers (PBMs) aimed at reducing prescription drug costs for patients and health plan sponsors. PBMs administer prescription drug plans for more than 266 million Americans with
Paying pharmacies more for dispensing medications will raise prescription drug costs without improving value.
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market and have advocated for policy changes that will increase generic and biosimilar uptake and put an end to brand manufacturers’ tactics to extend exclusivity on brand-name biologics. As more
Unlocking an Affordable Future: Key #1 Ensure System Sustainability ENSURE SYSTEM SUSTAINABILITY BY PROMOTING COMPETITION A competitive private market is the best way to manage drug costs. Interventions should be focused on fixing specific market failures or gaps rather than
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Administration’s Executive Order to resurrect the rebate rule. “The Administration’s decision last year to withdraw a proposed regulation on prescription drug
©2024 PCMA. All Rights Reserved.
